Sana Biotechnology Acquires Oscine Corp.

October 30, 2020

Sana Biotechnology announced the acquisition of Oscine Corp., integrating Oscine’s glial progenitor cell program and technologies into Sana’s broader platform to advance CNS therapies. Steve Goldman, Oscine’s scientific founder, joined Sana as Head of CNS Therapy; terms of the acquisition were not disclosed.

Buyers
Sana Biotechnology, Inc.
Targets
Oscine Corp.
Industry
Biotechnology
Location
New York, United States
Transaction Type
Buyout

Explore More

Build a buyer list for your deal

Find active buyers from recent acquisition patterns and move straight into outreach.